By Rob Kelly, Director, Investor Relations of Aurora
Early results of an ongoing study show that a cannabis oil produced by Aurora, has demonstrated promising results for children with epilepsy.
Researchers from the University of Saskatchewan have published the preliminary results of an ongoing and ground-breaking study showing that CanniMed® 1:20 cannabis oil, which is high in CBD and low in THC, can significantly reduce or even completely stop seizures in young children with severe and drug-resistant forms of epilepsy. The results, which appeared in the scientific journal
Acquired by Aurora in March 2018, CanniMed has 17 years’ experience in pharmaceutical cannabis cultivation. For 13 years, it was the sole supplier to Health Canada under the former medical marijuana system, producing products for thousands of Canadian patients.
The research study is being led by pediatric neurologist, Dr. Richard Huntsman of the University of Saskatchewan and the Cannabinoid Research Initiative of Saskatchewan.
“What makes these results really exciting is it opens up a treatment option for kids who have failed to respond to traditional medications,”
Dr. Huntsman said in a press release announcing the findings.
Dosing was based on the children’s weight. When CanniMed® 1:20 oil was administered at 10 to 12 milligrams per kilogram of weight per day, all of the study’s young participants experienced a reduction in seizures, most by more than 50 percent. Additionally, all of the seven participants, who were between the ages of one and 10 years old, saw improvements in their quality of life.
“Some of the improvements in quality of life were really dramatic with some of the children having huge improvements in their ability to communicate with their families,”
Dr. Huntsman explained in the press release.
“Some of these children started to talk or crawl for the first time. They became more interactive with their families and loved ones.”
The study investigators also found that the dosages used did not cause THC-related intoxication. This was an important finding because, until now, physicians have had very little dosing guidance for cannabis-based medicine for severe pediatric epilepsy, and health care providers have also expressed concerns about possible THC intoxication in children.
“These preliminary results provide much-needed data on the dosing of cannabinoid-based medication and help physicians better treat young patients with severe forms of epilepsy,”
says Dr. Kelly Narine, Aurora’s Vice President of Global Research and Medical Affairs.
The study’s research team independently selected CanniMed® 1:20 oil for the trial. CanniMed by Aurora and its parent company, Aurora Cannabis Inc., did not fund the study and remain at arm’s length from its administration.
CanniMed® 1:20 oil comes in a 60 ml bottle and contains a high amount of CBD (in the range of 16.0 to 24.0 mg/ml) and a small amount of THC (0.8 to 1.2 mg/ml). CanniMed’s high-quality oil products are made using dried cannabis flower without leaf, trimmings, or waste material and manufactured for the international medical cannabis market at Aurora Cannabis Inc.’s Aurora Prairie production facility in Saskatoon, Sask.
Research and innovation are at the heart of what Aurora does, and the company is increasing capacity and resources towards research and development to provide the highest level of care and products for our current and prospective patients. To boost this effort, Aurora has made an investment of $17.5 million over the next 18 months at the Aurora Prairie production and research facility.
The preliminary results of this epilepsy study are part of a more extensive 20-child study that concludes in December 2019.
“We look forward to seeing the results of the full study and are very hopeful that CanniMed® 1:20 oil will provide effective seizure relief and improvements in quality of life for these children, and by extension, their families,”
Dr. Narine added.
This is write by Rob Kelly, Director, Investor Relations of Aurora available here
Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best publication on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result.